Can You Take Retatrutide and Tirzepatide Together?

Nobody has tested retatrutide and tirzepatide together in a trial, so there's no known safe combined dose, and the Zepbound label says tirzepatide isn't recommended alongside any other GLP-1 receptor agonist. Retatrutide is one. The two drugs share two of their targets, the GIP and GLP-1 receptors, and each already causes nausea, vomiting and diarrhea on its own. A stack mostly doubles the part they have in common.

The question still gets asked a lot, mostly by people who moved from tirzepatide to retatrutide and felt their appetite come back. That problem is real. It has better answers than a second drug, and one of them is new this year.

What the Zepbound label says about combining them

The line is in the first section of the prescribing information, under limitations of use: "Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended." The Medication Guide puts it more plainly for patients. Zepbound "should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines."

Retatrutide activates the GLP-1 receptor, along with the GIP and glucagon receptors, so it falls inside that line. Mounjaro is the same molecule as Zepbound, sold for type 2 diabetes, so the overlap is identical whichever brand you're on.

Retatrutide has no label of its own yet, and its trials kept the two drugs apart. TRIUMPH-1, which randomized 2,339 adults, and TRIUMPH-5, the head-to-head trial against tirzepatide, both excluded anyone who had taken a weight-loss drug in the 90 days before screening. We checked all 33 retatrutide studies listed on ClinicalTrials.gov on September 29, 2026. None gives retatrutide on top of tirzepatide.

Where retatrutide and tirzepatide overlap

Tirzepatide works on two hormone receptors. Retatrutide works on those same two plus a third.

So adding tirzepatide to retatrutide adds nothing retatrutide doesn't already touch. It pushes harder on the two receptors they share. Whether those receptors have room for more at full doses is something no one has measured in people.

The long half-lives matter for the split-dosing idea that comes up in stacking threads. Injecting one drug on Monday and the other on Thursday doesn't separate them. With half-lives of 5 to 6 days, both are still circulating when the next dose of either goes in.

Retatrutide and tirzepatide together would stack the same side effects

Here's each drug alone at its top dose. These come from two different trials with different people and lengths, so read them as a rough guide to what each brings, not as a head-to-head.

On retatrutide 12 mg alone, about 4 in 10 people (42.4%) had nausea. Nobody can tell you what the number becomes when you add tirzepatide, because it has never been counted. The direction isn't in much doubt, though, since both columns come from the same kind of drug.

Heart rate is the other overlap. The Zepbound label reports an average rise of 1 to 3 beats per minute on tirzepatide. In retatrutide's Phase 2 trial, published in NEJM, heart rate rose with the dose, peaked at 24 weeks and then eased. Our retatrutide side effects guide covers both of these in more detail.

The Zepbound label also warns that vomiting and diarrhea can dry you out badly enough to injure the kidneys, and it lists gallbladder disease and inflammation of the pancreas (pancreatitis) among its warnings. The label ties most of the kidney cases to fluid lost through vomiting and diarrhea, which is the part a stack would add to.

Why people stack reta and tirz anyway

The threads on r/Retatrutide follow a pattern. Someone moves from tirzepatide to retatrutide, gets a few weeks in, and says the hunger blunting they had on tirzepatide is gone. They ask whether adding some tirzepatide back would quiet the food noise. Others ask whether to inject both on the same day or split them. That's a handful of Reddit threads, not a study.

Some websites answer with stacking protocols that list doses for both drugs. None of those protocols comes from a trial, because there isn't one to take them from.

Our read: in TRIUMPH-1, everyone started retatrutide at 2 mg and stepped up every 4 weeks, reaching 12 mg only after four steps. On that schedule, someone 3 weeks in after months on tirzepatide 10 or 15 mg would still be on 2 mg. A weaker appetite effect at that point is what the schedule predicts, and it's a reason to talk through the escalation with a doctor rather than add a second drug.

Retatrutide's Phase 2 trial also found that stomach side effects were partly reduced by starting at 2 mg instead of 4 mg. A stack does the opposite of a gentle start.

Switching instead of stacking

If you're on tirzepatide and want retatrutide, the usual question is how to move from one to the other, not how to run both. No trial has published a direct tirzepatide-to-retatrutide switch, so there's no official conversion. Our page on switching from tirzepatide sets out what's known and the questions to take to your prescriber.

What the trials do show is how retatrutide performs on its own. In TRIUMPH-1, people on 4 mg, reached with a single step up from 2 mg, lost 19.0% of their body weight on average at 80 weeks (the efficacy estimand, which assumes everyone stayed on treatment). Only 4.1% stopped because of side effects, against 4.9% on placebo. People on 12 mg lost 28.3%, with more side effects. The retatrutide dosage page lists every trial schedule.

TRIUMPH-5 is the trial that will say how the two compare. It has an estimated 800 adults with obesity, each randomized to one drug or the other, never both. As of September 2026 its record lists primary completion as November 2026, and no results are out.

If what you want from a second drug is a different pathway, the stacks people ask about next are ones like retatrutide and cagrilintide, which adds the amylin pathway instead of doubling GIP and GLP-1. That pairing hasn't been tested in people either.

If tirzepatide has stopped working for you

There's now a route for some people in this group. In June 2026 Lilly registered a pre-approval expanded access program for retatrutide. It's for adults with a BMI of 35 or more despite sticking with and tolerating the highest available dose of a weight-management drug, who have two or more serious obesity-related complications, and who can't join a retatrutide trial. Your doctor has to make the request; Lilly directs patients back to their own physician.

Clinical trials are the other route, but it's a narrow one. As of September 29, 2026, ClinicalTrials.gov lists only 2 retatrutide studies as recruiting: SYNERGY-Outcomes, Lilly's liver study, and a small Phase 2 study in China that isn't Lilly's. Every TRIUMPH obesity record we read also excludes anyone who took a weight-loss drug in the 90 days before screening. Our list of retatrutide clinical trials tracks what opens next. Lilly plans to file its US application, a biologics license application (BLA), in the first quarter of 2027.

Outside those routes, what's left is vials sold online as retatrutide. Lilly states that retatrutide "cannot be legally sold or marketed for human use", so none of those vials is Lilly's product, and nobody outside a trial can confirm what's inside. In a safety alert published September 14, 2026, Australia's TGA reported testing a vial sold as retatrutide after a user needed hospital treatment for uncontrollable vomiting. It held no retatrutide, just undeclared semaglutide at about 8 times the level in approved semaglutide products. Put that on top of tirzepatide and you're stacking two GLP-1 drugs without knowing it. If you're trying to make sense of listings of retatrutide for sale, that page explains what they are and how people read batch test reports.

If tirzepatide has stalled for you, bring a few months of weigh-ins to your doctor. Ask whether you've really plateaued on your current dose, whether you meet the expanded access criteria, and what a single-drug plan would look like.